follow your trial team's hypoglycaemia management plan Severe or persistent changes in mood, or any thoughts of self-harm or suicide whilst a causal link between GLP-1-based medicines and mood changes has not been established (regulatory reviews, including by the EMA, are ongoing), any significant psychological symptoms should be reported promptly [13] [14] Any allergic reaction, including rash or skin changes It is also important to report any new or worsening symptoms to your trial team, even if they seem minor
These incretin-based medications work by mimicking naturally occurring hormones that enhance insulin secretion, suppress glucagon release, slow gastric emptying, and reduce appetite through central nervous system pathways
Curcumin, a constituent of turmeric, has demonstrated antiplatelet effects in vitro
That means if you are reading this right now, retatrutide is likely 18 to 24 months away from being something you can actually obtain with a prescription
By providing your phone number, you agree to receive SMS messages from us